ReviewMicroorganisms2022
Viral Vector Vaccine Development and Application during the COVID-19 Pandemic.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Vaccines for preventing infections in adults with solid tumours.The Cochrane database of systematic reviews · 2025Pooled it
- Comparative efficacy of leading COVID-19 vaccines: A network meta-analysis.The Indian journal of medical research · 2025Pooled it
- Next-generation mucosal vaccines for respiratory viruses: Immunological correlates, platform design and clinical translation.World journal of virology · 2026Review
- E2 Protein of Chikungunya Virus: A Narrative Review of Its Potential as a Therapeutic Target.Current drug targets · 2026Review
- Review
- Viral correlates of protection and the multifarious interactions of B and T cells.Human vaccines & immunotherapeutics · 2025Review
- In silico design of a multi-epitope vaccine against the triple negative breast cancer.Scientific reports · 2025Article
- Antiviral Inactivated Vaccines: Looking to the Past to Face the Future-A Narrative Review.Vaccines · 2025Review
- Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity.NPJ vaccines · 2025Article
- Review
- Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.Vaccines · 2025Review
- Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases.Frontiers in immunology · 2025Review
- Patent landscape of nanotechnology - based nucleic acid delivery systems for breast cancer therapies.Frontiers in oncology · 2025Article
- Next-generation vaccines against bacterial pathogens: mRNA and beyond.Frontiers in immunology · 2025Review
- Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases.Therapeutic advances in neurological disorders · 2025Article
- Article
- Safety pharmacology of human endogenous retrovirus-enveloped baculoviral DNA vaccines against SARS-CoV-2 in Sprague-Dawley rats and beagle dogs.Vaccine: X · 2024Article
- Influenza B Virus Vaccine Innovation through Computational Design.Pathogens (Basel, Switzerland) · 2024Review
- Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review.Vaccines · 2024Review
- The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.The Journal of infectious diseases · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
With the accumulation of mutations in SARS-CoV-2 and the continuous emergence of new variants, the importance of developing safer and effective vaccines has become more prominent in combating the COVID-19 pandemic. Both traditional and genetically engineered vaccines have contributed to the prevention and control of the pandemic. However, in recent years, the trend of vaccination research has gradually transitioned from traditional to genetically engineered vaccines, with the development of viral vector vaccines attracting increasing attention. Viral vector vaccines have several unique advantages compared to other vaccine platforms. The spread of Omicron has also made the development of intranasal viral vector vaccines more urgent, as the infection site of Omicron is more prominent in the upper respiratory tract. Therefore, the present review focuses on the development of viral vector vaccines and their application during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.